Advancements in molecular genetics and targeted biological therapies are transforming the treatment landscape for rare genetic tumor syndromes. Detailed analysis within the Neurofibromatoses Type Ii Therapecutics Market report demonstrates that NF2 (neurofibromatosis type 2, characterized by NF2-related schwannomatosis) results from loss-of-function mutations in the merlin tumor suppressor...
About
Terms
Privacy
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek